中国实验血液学杂志2024,Vol.32Issue(6) :1917-1922.DOI:10.19746/j.cnki.issn1009-2137.2024.06.043

BRAF V600E突变与儿童朗格汉斯细胞组织细胞增生症的临床特征及预后的相关性分析

Correlation of BRAF V600E Mutation with Clinical Features and Prognosis of Langerhans Cell Histiocytosis in Cildren

李希 肖莉 罗明珠 雷小英 刘海燕 姚新原 郭玉霞 窦颖 于洁
中国实验血液学杂志2024,Vol.32Issue(6) :1917-1922.DOI:10.19746/j.cnki.issn1009-2137.2024.06.043

BRAF V600E突变与儿童朗格汉斯细胞组织细胞增生症的临床特征及预后的相关性分析

Correlation of BRAF V600E Mutation with Clinical Features and Prognosis of Langerhans Cell Histiocytosis in Cildren

李希 1肖莉 1罗明珠 1雷小英 1刘海燕 1姚新原 1郭玉霞 1窦颖 1于洁1
扫码查看

作者信息

  • 1. 重庆医科大学附属儿童医院,国家儿童健康与疾病临床医学研究中心,儿科学重庆市重点实验室,儿童发育疾病研究教育部重点实验室,儿童发育重大疾病国家国际科技合作基地,重庆 400014
  • 折叠

摘要

目的:探讨儿童朗格汉斯细胞组织细胞增生症(LCH)基因突变情况,分析BRAF V600E基因突变与LCH的临床特征及预后的相关性,为临床诊治提供参考.方法:采用荧光PCR法检测78例LCH患儿石蜡包埋组织样本的基因突变情况,分析LCH患儿BRAF V600E基因突变与其临床特征及预后之间的相关性.结果:78例患儿中BRAF V600E基因突变阳性41例(52.6%),MAP2K1基因突变阳性8例(10.3%),BRAF Exon 12突变阳性1例(1.3%),ARAF基因突变阳性1例(1.3%),PIK3CA基因突变阳性1例(1.3%).BRAF V600E基因突变与LCH患儿性别、年龄、多系统受累、危险器官受累、中枢神经(CNS)危险性病变、早期治疗反应无明显统计学相关性(P>0.05),与LCH复发及无事件生存(EFS)也无明显统计学相关性(P>0.05).结论:LCH是一种炎性髓系肿瘤,BRAF V600E基因突变与其临床特征、早期治疗反应、复发及预后无关.

Abstract

Objective:To explore the gene mutations of Langerhans cell histiocytosis in children,and to analyze the correlation of BRAF V600E mutation with clinical features and prognosis of LCH,so as to provide reference for clinical diagnosis and treatment. Methods:Fluorescence PCR was used to detect gene mutations in paraffin-embedded tissue samples from 78 children with LCH,and the correlation of BRAF V600E mutation with clinical characteristics and prognosis of LCH in children was analyzed. Results:Among the 78 children,41 cases (52.6%) had BRAF V600E mutation,8 cases (10.3%) had MAP2K1 mutation,1 case (1.3%) had BRAF Exon 12 mutation,1 case (1.3%) had ARAF mutation,and 1 case (1.3%) had PIK3CA mutation. BRAF V600E mutation was not significantly correlated with sex,age,multisystem involvement,risk-organ involvement,CNS-risk lesions,and early treatment response in children with LCH (P>0.05),and it was also not significantly correlated with the recurrence and event-free survival (EFS) of children with LCH (P>0.05). Conclusion:LCH is an inflammatory myeloid tumor. BRAF V600E mutation is not correlated with clinical features,early treatment response,recurrence and prognosis of LCH.

关键词

朗格汉斯细胞组织细胞增生症/BRAF/V600E/基因突变/预后

Key words

Langerhans cell histiocytosis/BRAF V600E/gene mutation/prognosis

引用本文复制引用

出版年

2024
中国实验血液学杂志
中国病理生理学会

中国实验血液学杂志

CSTPCDCSCD北大核心
影响因子:0.988
ISSN:1009-2137
段落导航相关论文